EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Albuminuria drives hyperlipidemia in patients with Alport syndrome

Oliver Gross iD, Annika Jens, Agne Cerkauskaite-Kerpauskiene, Valentine Gillion, Mira Choi, Jan Halbritter iD, Yanqin Zhang, Fang Wang, Jie Ding, Ilva Bever, Jana Wenzlitschke, Kathleen J Claes iD und 2 weitere

Nephrology Dialysis Transplantation · 15.05.2026

DOI: 10.1093/ndt/gfag100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 15.05.2026. Verfasst von Oliver Gross und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BMBF, DFG, European Renal Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Hypercholesterolemia is a major driver of cardiovascular disease, a leading cause of premature mortality in patients with chronic kidney disease (CKD). Despite their typically young age, patients with Alport syndrome (AS), the second most prevalent genetic cause of CKD, may face a disproportionately high risk of hypercholesterolemia. This study investigates whether increased albuminuria precipitates hyperlipidemia in this population to a degree comparable with general CKD cohorts, while further delineating the risk factors underlying this development.

Methods

This was a multicenter, observational, non-interventional, and retrospective study.

Results

Among 459 patients with AS, 59.3% had hypercholesterolemia and 58.5% had elevated low-density lipoprotein cholesterol (LDL-C). Despite lower estimated glomerular filtration rate (eGFR) and higher albuminuria, patients receiving lipid-lowering therapy (LLT) had significantly lower total cholesterol levels compared to the untreated patients (193.6 ± 55.2 mg/dl vs. 208.2 ± 51.0 mg/dl; P =.044). Similarly, LDL-C levels were significantly lower in the treatment group (111.6 ± 51 mg/dl, n = 59) compared with the untreated group (124.3 ± 40.2 mg/dl, n = 238; P =.041). Multivariable regression analysis adjusted for age, sex body mass index (BMI), eGFR, and LLT revealed that albuminuria was a significant independent predictor of total cholesterol (β = 0.315; P < .001) and LDL-C levels (β = 0.242; P < .001). Male sex was associated with significantly higher LDL-C and lower high-density lipoprotein cholesterol (HDL-C) levels. Conversely, eGFR and BMI were not significant predictors of cholesterol levels. This association was also observed in the pediatric cohort (n = 44), where albuminuria was the only independent predictor of cholesterol (β = 0.728; P < .001).

Conclusions

Hypercholesterolemia is highly prevalent in young patients with AS and is primarily driven by the severity of albuminuria, rather than other risk factors such as obesity or eGFR decline. These findings highlight a critical gap in current guidelines, support the implementation of early lipid screening and suggest that risk-adapted management may be necessary to prevent long-term cardiovascular complications.

Schlagwörter

Stichwörter der Autor:innen

Alport syndromealbuminuriacardiovascular riskdyslipidemialipid-lowering therapy

Autor:innen und Institutionen

  • Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany.
  • Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Clinic of Gastroenterology, Nephro-Urology and Surgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Nephrology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  • Department of Pediatrics, Peking University First Hospital, Beijing, China.
  • Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium.

ORCID-Profile: Oliver Gross, Jan Halbritter, Kathleen J Claes

Förderung

  • BMBF
  • DFG
  • European Renal Association

Zitieren

APA

Gross, O., Jens, A., Cerkauskaite-Kerpauskiene, A., Gillion, V., Choi, M., Halbritter, J., Zhang, Y., Wang, F., Ding, J., Bever, I., Wenzlitschke, J., Claes, K. J., Wallbach, M., & Boeckhaus, J. (2026). Albuminuria drives hyperlipidemia in patients with Alport syndrome. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag100

Vancouver

Gross O, Jens A, Cerkauskaite-Kerpauskiene A, Gillion V, Choi M, Halbritter J, et al. Albuminuria drives hyperlipidemia in patients with Alport syndrome. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag100

BibTeX
@article{Gross2026,
  author = {Gross, Oliver and Jens, Annika and Cerkauskaite-Kerpauskiene, Agne and Gillion, Valentine and Choi, Mira and Halbritter, Jan and Zhang, Yanqin and Wang, Fang and Ding, Jie and Bever, Ilva and Wenzlitschke, Jana and Claes, Kathleen J and Wallbach, Manuel and Boeckhaus, Jan},
  title = {Albuminuria drives hyperlipidemia in patients with Alport syndrome},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag100}
}
Kostenlos starten →